Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B
NCT04850950Phase 4Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of tenofovir alafenamide in hepatitis B (HBV) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Birth defects at 7 months and Rate of perinatal transmission of hepatitis B virus at 7 months. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04850950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850950.